Page 37 - Read Online

Llamoza-Torres et al. Metab Target Organ Damage 2024;4:40 https://dx.doi.org/10.20517/mtod.2024.64 Page 17 of 18

risk assessment. Liver Int 2024;Online ahead of print. DOI PubMed
108. Burke L, Hinkson A, Haghnejad V, Jones R, Parker R, Rowe IA. Hepatocellular carcinoma risk scores for non-viral liver disease: a
systematic review and meta-analysis. JHEP Reports 2024;Online ahead of print. DOI
109. Kalligeros M, Henry L, Younossi ZM. Metabolic dysfunction-associated steatotic liver disease and its link to cancer. Metabolism
2024;160:156004. DOI PubMed
110. Thomas JA, Kendall BJ, Dalais C, Macdonald GA, Thrift AP. Hepatocellular and extrahepatic cancers in non-alcoholic fatty liver
disease: a systematic review and meta-analysis. Eur J Cancer 2022;173:250-62. DOI PubMed
111. Day CP, James OF. Steatohepatitis: a tale of two “hits”? Gastroenterology 1998;114:842-5. DOI PubMed
112. Kazankov K, Jørgensen SMD, Thomsen KL, et al. The role of macrophages in nonalcoholic fatty liver disease and nonalcoholic
steatohepatitis. Nat Rev Gastroenterol Hepatol 2019;16:145-59. DOI PubMed
+
113. Hendrikx T, Porsch F, Kiss MG, et al. Soluble TREM2 levels reflect the recruitment and expansion of TREM2 macrophages that
localize to fibrotic areas and limit NASH. J Hepatol 2022;77:1373-85. DOI PubMed
114. Zucman-Rossi J, Villanueva A, Nault JC, Llovet JM. Genetic landscape and biomarkers of hepatocellular carcinoma.
Gastroenterology 2015;149:1226-39.e4. DOI PubMed
115. Sia D, Jiao Y, Martinez-Quetglas I, et al. Identification of an immune-specific class of hepatocellular carcinoma, based on molecular
features. Gastroenterology 2017;153:812-26. DOI PubMed
116. Jaitin DA, Adlung L, Thaiss CA, et al. Lipid-associated macrophages control metabolic homeostasis in a Trem2-dependent manner.
Cell 2019;178:686-98.e14. DOI PubMed PMC
117. Fredrickson G, Florczak K, Barrow F, et al. TREM2 macrophages mediate the beneficial effects of bariatric surgery against MASH.
Hepatology 2024;Online ahead of print. DOI PubMed
118. Ding T, Xu J, Wang F, et al. High tumor-infiltrating macrophage density predicts poor prognosis in patients with primary
hepatocellular carcinoma after resection. Hum Pathol 2009;40:381-9. DOI PubMed
119. Kuang DM, Zhao Q, Peng C, et al. Activated monocytes in peritumoral stroma of hepatocellular carcinoma foster immune privilege
and disease progression through PD-L1. J Exp Med 2009;206:1327-37. DOI PubMed PMC
120. Wang Q, Lin Y, Yu W, Chen X, He Q, Ye Z. The core role of macrophages in hepatocellular carcinoma: the definition of molecular
subtypes and the prognostic risk system. Front Pharmacol 2023;14:1228052. DOI PubMed PMC
121. Zhao S, Jang C, Liu J, et al. Dietary fructose feeds hepatic lipogenesis via microbiota-derived acetate. Nature 2020;579:586-91. DOI
PubMed PMC
122. Hu C, Xu B, Wang X, et al. Gut microbiota-derived short-chain fatty acids regulate group 3 innate lymphoid cells in HCC.
Hepatology 2023;77:48-64. DOI PubMed PMC
123. Qin S, Chen M, Cheng AL, et al; IMbrave050 investigators. Atezolizumab plus bevacizumab versus active surveillance in patients
with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial.
Lancet 2023;402:1835-47. DOI PubMed
124. Lencioni R, Kudo M, Erinjeri J, et al. EMERALD-1: a phase 3, randomized, placebo-controlled study of transarterial
chemoembolization combined with durvalumab with or without bevacizumab in participants with unresectable hepatocellular
carcinoma eligible for embolization. JCO 2024;42:LBA432. DOI
125. Llovet J, Finn R, Ren Z, et al. LBA3 transarterial chemoembolization (TACE) with or without lenvatinib (len) + pembrolizumab
(pembro) for intermediate-stage hepatocellular carcinoma (HCC): phase III LEAP-012 study. Annals of Oncology 2024;35:S1229.
DOI
126. Llovet JM, Ricci S, Mazzaferro V, et al; SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma. N Engl
J Med 2008;359:378-90. DOI PubMed
127. Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced
hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009;10:25-34. DOI PubMed
128. Kudo M, Finn RS, Qin S, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular
carcinoma: a randomised phase 3 non-inferiority trial. Lancet 2018;391:1163-73. DOI PubMed
129. Finn RS, Qin S, Ikeda M, et al; IMbrave150 Investigators. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma.
N Engl J Med 2020;382:1894-905. DOI PubMed
130. Ren Z, Xu J, Bai Y, et al; ORIENT-32 study group. Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in
unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 study. Lancet Oncol 2021;22:977-90. DOI
PubMed
131. Kelley RK, Rimassa L, Cheng AL, et al. Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma
(COSMIC-312): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol 2022;23:995-1008. DOI PubMed
132. Abou-Alfa GK, Lau G, Kudo M, et al. Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma. NEJM Evid
2022;1:EVIDoa2100070. DOI PubMed
133. Qin S, Kudo M, Meyer T, et al. Tislelizumab vs sorafenib as first-line treatment for unresectable hepatocellular carcinoma: a phase 3
randomized clinical trial. JAMA Oncol 2023;9:1651-9. DOI PubMed PMC
134. Qin S, Chan SL, Gu S, et al; CARES-310 Study Group. Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for
unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study. Lancet 2023;402:1133-
46. DOI PubMed